Olema Pharmaceuticals (OLMA) Revenue & Revenue Breakdown
Olema Pharmaceuticals Revenue Highlights
00
Olema Pharmaceuticals Revenue by Period
Olema Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Olema Pharmaceuticals generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Olema Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $364.00K | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $1.88M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | - |
Olema Pharmaceuticals generated - in revenue during Q2 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Olema Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| DAWN | Day One Biopharmaceuticals | $131.16M | $33.91M |
| URGN | UroGen Pharma | $90.40M | $20.25M |
| NRIX | Nurix Therapeutics | $54.55M | $7.89M |
| ABSI | Absci | $4.53M | $593.00K |
| KOD | Kodiak Sciences | - | - |
| ATXS | Astria Therapeutics | - | - |
| OLMA | Olema Pharmaceuticals | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| ERAS | Erasca | - | - |
| TYRA | Tyra Biosciences | - | - |
| OMER | Omeros | - | - |